Cetuximab scFv-Modified 5-FU Loaded Chitosan Nanoparticles: "A Novel Therapeutic Platform."
scFv-CS/5-FU NPs showed remarkable anti-CRC activity. This novel targeting delivery system reduced the effective dose of 5-FU which is of vital importance to decrease the devastating side effects of chemotherapy.
Authors
- Fariba Esmaeili (ORCID: https://orcid.org/0000-0003-2936-5890)
- Yeganeh Talebkhan Garoosi (ORCID: https://orcid.org/0000-0003-1988-4419)
- Babak Negahdari (ORCID: https://orcid.org/0000-0002-8742-9138)
- Mohammad Ali Mazlomi (ORCID: https://orcid.org/0000-0001-5370-3111)
- Farshid Zandsalimi (ORCID: https://orcid.org/0000-0002-2329-3884)
- Khadijeh Falahzadeh (ORCID: https://orcid.org/0000-0003-4401-5485)
- Masumeh Jalalvand (ORCID: https://orcid.org/0000-0002-5473-147X)
- Gholamreza Shahsavari (ORCID: https://orcid.org/0000-0003-2840-5192)
- Elham Bayat (ORCID: https://orcid.org/0000-0003-0502-7870)
Institutions
- Pasteur Institute of Iran (IR)
- Lorestan University of Medical Sciences (IR)
- Biotechnology Research Center (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Current Pharmaceutical Biotechnology
- Published
- 2024-10-31
- DOI
- https://doi.org/10.2174/0113892010340791241025033549
- Citations
- 2
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.35